List of Excipients in Branded Drug ERYTHROCIN LACTOBIONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	ERYTHROCIN LACTOBIONATE	erythromycin lactobionate	0409-6482	WATER

Generic Drugs Containing ERYTHROCIN LACTOBIONATE

Company	Ingredient	NDC	Excipient
Hospira Inc	erythromycin lactobionate	0409-6476	WATER

What are the Most Frequently-Used Excipients in ERYTHROCIN LACTOBIONATE?

# Of NDCs	Excipient
1	WATER

Erythrocin Lactobionate Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Erythrocin Lactobionate is an injectable erythromycin product containing erythromycin lactobionate, a water-soluble salt of erythromycin. Its commercial value is no longer driven by active-ingredient exclusivity. The strongest opportunities are sterile manufacturing efficiency, ready-to-use delivery, hospital supply reliability, pediatric and neonatal dosing, and differentiated administration formats.

The formulation has a relatively simple excipient profile because erythromycin lactobionate provides the solubility needed for intravenous use. A new entrant would compete primarily on quality, stability, convenience, shortage mitigation, and total treatment cost rather than on a conventional composition-of-matter patent.

What is Erythrocin Lactobionate?

Erythrocin Lactobionate is an intravenous erythromycin formulation supplied as a sterile powder for reconstitution. The labeled product contains erythromycin lactobionate equivalent to 500 mg of erythromycin per vial. The product is administered after reconstitution and dilution for intravenous infusion. It is used when oral erythromycin is not feasible or when parenteral therapy is clinically required [1].

Product attribute	Erythrocin Lactobionate
Active ingredient	Erythromycin lactobionate
Active-moiety equivalent	500 mg erythromycin per vial
Dosage form	Sterile powder for injection
Route	Intravenous infusion
Preservative profile	Conventional single-dose sterile presentation; no routine antimicrobial preservative advantage
Primary formulation function	Improve aqueous solubility and permit parenteral administration
Regulatory pathway for a copy	Generally an ANDA if an eligible reference listed drug is available
Biosimilar exposure	None
Main commercial setting	Hospitals, emergency care, inpatient pediatrics, and patients unable to take oral therapy

Erythromycin lactobionate is the active pharmaceutical ingredient in salt form, not an inactive excipient. The lactobionate counterion improves the injectable formulation’s water solubility. This distinction matters for patent searching, regulatory sameness, and formulation design.

What excipients are used in Erythrocin Lactobionate?

The core commercial formulation is a low-excipient sterile powder. The product is reconstituted with Sterile Water for Injection and then diluted in a compatible intravenous solution according to the prescribing information [1].

The formulation strategy has four main characteristics:

1. The active salt supplies the principal solubilization function.
2. The vial avoids the need for a complex oral excipient system.
3. The product is designed for aseptic reconstitution and infusion.
4. The formulation must control pH, particulate formation, chemical degradation, and container compatibility.

Potential excipient categories for a development program include:

Excipient or component	Formulation purpose	Commercial relevance
Erythromycin lactobionate	Soluble erythromycin salt	Defines the active salt and injectable product profile
Sterile Water for Injection	Reconstitution vehicle	Required at the point of use unless a ready-to-use product is developed
Sodium chloride or dextrose solution	Further dilution vehicle	Supports hospital administration and pharmacy protocols
pH-adjusting agent	Controls stability and tolerability	May affect degradation, compatibility, and infusion-site reactions
Bulking agent	Supports lyophilized cake or powder structure	Relevant to a new lyophilized or dual-chamber product
Chelating agent	May reduce trace-metal degradation	Requires compatibility and safety justification
Surfactant	May reduce adsorption or particulate formation	More relevant to concentrated or container-contacting formulations
Preservative	Multidose microbiological protection	Usually less attractive for intravenous single-dose products

A development program should not add excipients merely to create a longer ingredient list. Each added component increases extractables, leachables, toxicology, compatibility, and regulatory burden. The preferred baseline is a sterile, preservative-free, low-excipient presentation with validated reconstitution and infusion stability.

What formulation patents protect Erythrocin Lactobionate?

The original erythromycin active-ingredient and salt technology is old and does not provide a practical modern exclusivity position for Erythrocin Lactobionate. The commercial opportunity therefore depends on new formulation claims, device claims, manufacturing claims, or packaging claims.

A defensible new patent estate could cover:

• A stable lyophilized erythromycin lactobionate cake with defined residual moisture.
• A specified pH range that reduces degradation during reconstitution.
• A concentrated formulation that reduces infusion volume.
• A ready-to-use intravenous bag with a defined shelf life.
• A dual-chamber vial that separates dry erythromycin lactobionate from the diluent.
• A polymer container or stopper system that limits adsorption or leachables.
• A formulation with a defined impurity profile after extended storage.
• A pediatric or neonatal presentation with a measured-dose delivery system.
• A manufacturing process that improves sterile yield or reduces visible and subvisible particles.

Patent claims based only on routine selection of common excipients are vulnerable to obviousness challenges. Stronger claims would connect the excipient choice to an unexpected stability, compatibility, or manufacturing result.

When does Erythrocin Lactobionate lose exclusivity?

Erythromycin has been marketed for decades. The original active-moiety exclusivity and early product patents have expired. Erythrocin Lactobionate should therefore be analyzed as an off-patent injectable antibiotic rather than as a protected branded product.

Exclusivity category	Commercial assessment
Composition-of-matter protection	Expired for erythromycin and established erythromycin salts
Original formulation protection	Expired or commercially immaterial
New chemical entity exclusivity	Not applicable to this legacy product
Orphan exclusivity	Not applicable based on the established product profile
Pediatric exclusivity	No product-specific extension should be assumed
Reference-product patent exposure	Limited relative to modern branded drugs
Biosimilar exclusivity	Not applicable
New formulation exclusivity	Available only through a new qualifying product and patent strategy

The principal barrier is regulatory and operational, not foundational patent exclusivity. A company could obtain limited market protection for a new formulation through a 505(b)(2) application, depending on the product’s differences from the reference product. A therapeutically equivalent copy would generally pursue the ANDA route under section 505(j) of the Federal Food, Drug, and Cosmetic Act [2].

What is the Orange Book status of Erythrocin Lactobionate?

The Orange Book is relevant to the extent that a specific erythromycin lactobionate injection is listed as a reference product and has current marketing status. The database separates reference-listed drugs, patents, exclusivity, and therapeutic-equivalence information [3].

For an Erythrocin Lactobionate investment decision, the key Orange Book questions are:

• Whether the branded product is currently listed as the reference listed drug.
• Whether the product is designated discontinued for reasons other than safety or effectiveness.
• Whether any patents are listed against the injection.
• Whether an approved generic has a therapeutic-equivalence code.
• Whether the dosage form and strength support an ANDA rather than a 505(b)(2) application.

The practical conclusion is that a new entrant should not base its strategy on Orange Book patent blocking. Any meaningful exclusivity would need to arise from a new product configuration, a formulation patent, a delivery system, or a regulatory designation.

Are Paragraph IV challenges relevant to Erythrocin Lactobionate?

Paragraph IV litigation is likely to have limited relevance because the core erythromycin lactobionate technology is old and the injectable product does not represent a typical modern patent-heavy reference product.

A Paragraph IV filing would matter only if the proposed generic must certify against one or more unexpired Orange Book patents. For a newly developed ready-to-use or concentrated formulation, the sponsor may instead pursue a 505(b)(2) strategy and rely on the established erythromycin literature and reference-product data while addressing formulation-specific differences.

The litigation risk profile is therefore asymmetric:

Strategy	Main legal risk
Conventional sterile powder ANDA	Patent risk is low; approval, bioequivalence, manufacturing, and supply risk dominate
Ready-to-use infusion product	Formulation and packaging patents may be asserted
Concentrated injection	Stability, local tolerability, and non-infringement issues become more important
Dual-chamber presentation	Device and container patents may affect freedom to operate
New excipient system	Patentability and regulatory justification must be established

What formulation strategy offers the strongest commercial opportunity?

Ready-to-use intravenous bags

A ready-to-use bag eliminates pharmacy reconstitution and reduces compounding steps. Its value is highest in emergency departments, intensive-care units, pediatric wards, and hospitals with constrained pharmacy capacity.

The main development requirements are:

• Long-term chemical stability in the final container.
• Sterility over the labeled shelf life.
• Low particulate burden.
• Compatibility with common infusion sets.
• Protection from light and temperature excursions.
• A container that limits drug loss and extractables.
• A practical concentration and infusion volume.

A ready-to-use bag could command a price premium if it reduces preparation time, medication-error risk, and waste. The commercial case is strongest where hospitals measure pharmacy labor and administration efficiency.

Dual-chamber vial

A dual-chamber vial keeps erythromycin lactobionate separate from the diluent until activation. This format preserves a dry-product stability profile while reducing manual preparation.

The principal advantages are:

• Lower reconstitution burden.
• Reduced contamination risk.
• Improved workflow for urgent dosing.
• Potentially longer shelf life than a premixed liquid.
• Compatibility with automated dispensing systems.

The disadvantage is device cost. The format requires a reliable activation mechanism, container-closure validation, and human-factors testing.

Pediatric and neonatal presentations

Erythromycin has an established role in pediatric care, while intravenous administration can be difficult when dose volumes are small. Commercial products could provide:

• Lower-strength vials.
• Ready-to-use diluted syringes for institutional use.
• Unit-dose presentations.
• Clearly calibrated infusion volumes.
• Labels designed for weight-based dosing.

A pediatric product must address dosing accuracy, preservative avoidance, low extractable burden, and compatibility with neonatal infusion hardware. A low-volume presentation could differentiate the product without changing the active moiety.

Improved lyophilized powder

The lowest-risk opportunity is an improved sterile powder with better reconstitution time, reduced foaming, lower residual moisture, or better stability after dilution. This approach retains the established hospital workflow while improving handling and supply reliability.

The patent position would be stronger if the process produces a measurable technical effect, such as a defined impurity reduction or improved reconstitution performance.

How does Erythrocin Lactobionate compare with competing erythromycin products?

Product type	Primary route	Formulation advantage	Commercial limitation
Erythromycin lactobionate injection	Intravenous	Parenteral use and soluble salt form	Reconstitution and infusion requirements
Oral erythromycin tablets or capsules	Oral	Low administration cost	Limited use when oral therapy is not possible
Erythromycin oral suspension	Oral	Pediatric dosing flexibility	Stability, taste, and adherence issues
Azithromycin injection	Intravenous	Alternative macrolide with established hospital use	Different clinical profile and competitive positioning
Clarithromycin injection	Intravenous in selected markets	Alternative macrolide formulation	Different regulatory and market availability
Other intravenous antibiotics	Intravenous	Broader indications or newer clinical positioning	Higher cost, stewardship restrictions, or different safety profiles

Erythromycin lactobionate is most competitive where erythromycin-specific clinical use is required and intravenous delivery has operational value. It is less attractive as a broad hospital antibiotic because newer macrolides and other agents may offer simpler dosing or wider indications.

What generic entry risks exist?

Generic entry risk is high for a conventional erythromycin lactobionate powder because the active salt and dosage form are established. The main risks are:

• Price erosion after multiple suppliers enter.
• Hospital purchasing consolidation.
• Low unit volume relative to manufacturing complexity.
• Sterile-product quality events.
• Raw-material supply interruptions.
• Inadequate capacity for aseptic filling and lyophilization.
• Product discontinuation if margins do not support inventory requirements.

A generic sponsor needs a cost advantage or a supply advantage. A conventional copy with no operational differentiation may have limited returns despite low patent risk.

What manufacturing and IP barriers affect commercialization?

Sterile injectable manufacturing is the main practical barrier. Erythromycin lactobionate products require validated control of:

• Aseptic processing.
• Sterile filtration or sterilization strategy.
• Fill weight and potency uniformity.
• Residual moisture.
• Reconstitution time.
• Visible and subvisible particles.
• Container-closure integrity.
• Post-reconstitution stability.
• Infusion-line compatibility.
• Degradation products and microbiological quality.

The manufacturing model should favor a facility with established lyophilization, sterile powder filling, and injectable quality systems. Contract manufacturing can reduce capital requirements but may create capacity and supply-priority risks.

The strongest IP strategy combines formulation and process claims. Packaging and device claims should be included for ready-to-use and dual-chamber formats. Method-of-use claims may provide limited value because erythromycin indications are established and broad treatment claims may face prior-art challenges.

What is the commercial opportunity for a new Erythrocin Lactobionate product?

The most attractive opportunities rank as follows:

1. Ready-to-use intravenous bag with stable shelf life.
2. Dual-chamber vial for rapid reconstitution.
3. Pediatric or neonatal unit-dose presentation.
4. Improved lyophilized powder with faster reconstitution.
5. Supply-focused generic powder for injection.

A conventional generic has the lowest technical risk but also the weakest differentiation. A ready-to-use product has higher development and regulatory costs, but it can compete on pharmacy labor, medication safety, and hospital workflow.

Revenue exposure is likely to be modest compared with large branded antibiotics. The relevant commercial metric is not national prescription volume alone. It is institutional purchasing, contract coverage, shortage substitution, and the share of hospitals that maintain intravenous erythromycin on formulary.

Key Takeaways

• Erythrocin Lactobionate is an intravenous erythromycin lactobionate formulation supplied as sterile powder for reconstitution.
• The lactobionate salt is the principal solubility-enabling component; the product does not require a complex excipient system.
• Original erythromycin exclusivity has expired, making patent blocking a limited concern.
• Conventional generic entry is likely to face regulatory and manufacturing hurdles rather than composition-of-matter barriers.
• The strongest new-product opportunities are ready-to-use bags, dual-chamber vials, pediatric presentations, and improved lyophilized powders.
• Formulation patents should claim measurable stability, compatibility, reconstitution, impurity, or container-performance results.
• Biosimilar risk does not apply because erythromycin is a small-molecule antibiotic.
• The commercial case depends on sterile supply reliability, hospital workflow savings, and product differentiation.

FAQs

Can erythromycin lactobionate be reformulated as a premixed infusion?

Yes. A premixed infusion is technically feasible, but the formulation must demonstrate adequate shelf life, container compatibility, sterility, particulate control, and post-dilution stability under the intended storage and administration conditions.

Is erythromycin lactobionate protected by a new chemical entity patent?

No. Erythromycin and its established salt forms are legacy technologies. Any meaningful current protection would need to come from a later formulation, device, packaging, or manufacturing patent.

Would a ready-to-use erythromycin product require an ANDA or a 505(b)(2) application?

The pathway depends on the degree of sameness to the reference product. A therapeutically equivalent copy may qualify for an ANDA. A product with a materially different formulation, concentration, container, or delivery system may require a 505(b)(2) application [2].

Are excipient patents commercially important for erythromycin lactobionate?

They can be important for a differentiated product, but generic use of conventional excipients is unlikely to create durable protection. The strongest claims connect the excipient system to a demonstrated technical result.

Is a shortage-supply strategy viable for Erythrocin Lactobionate?

Yes. Sterile injectable shortages create an opportunity for a manufacturer with reliable active-substance sourcing, validated aseptic capacity, and hospital distribution. The strategy requires durable supply economics because shortage-driven demand may decline when competing products return.

References

1. DailyMed. (n.d.). Erythrocin lactobionate for injection prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book